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INTRODUCTION
What Are Telomeres?
Telomeres are the noncoding regions of DNA that pro-
vide a protective cap at the ends of eukaryotic chromo-
somes. Telomeres protect encoding DNA from enzymatic
breakdown and prevent dicentric fusion and other chromo-
some aberrations. The mechanism for regulating telomere
length is not entirely known but is partly attributed to the
ribonucleoprotein reverse transcriptase, known as telom-
erase [1]. It has been shown that telomeres shorten 50 to
150 base pairs (bp) per cell division in most somatic tissues,
which, in general, do not express telomerase [2-4]. In con-
trast, telomeres do not progressively shorten in germ line
tissues that do express telomerase [3]. Induction of telom-
erase appears to maintain telomere length and postpone
senescence [5-7]. Constitutive expression of telomerase is
generally a requirement for immortalization of cells [8-10].
TELOMERE SHORTENING AFTER HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Several investigators have addressed the issue of telom-
ere shortening in nucleated blood cells of stem cell trans-
plant recipients. It was hypothesized that replicative
demand imposed on donor stem cells may result in sub-
stantial shortening of telomeres, thereby potentially com-
promising the long-term function of the marrow graft.
Most studies involving adult and pediatric patients have
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ABSTRACT
Telomeres serve to maintain the structural integrity of chromosomes, yet each somatic cell division is associated
with a decrease in telomere length. The cumulative decrease in telomere length can impose an upper limit for the
number of cell divisions that can occur before a cell senesces. When studied in vitro with fibroblasts, this limit is
referred to as the Hayflick limit and usually occurs after 40 to 80 cell doublings. In theory, a similar replicative
potential in a hematopoietic stem cell could support hematopoiesis in a person for more than 100 years. However,
stem cells differentiate, and the telomere length differs among chromosomes within a single cell, among cell types,
and among age-matched individuals. This variation in telomere length raises the possibility that long-term hemato-
poiesis by transplanted stem cells could, depending on the telomere length of the engrafted stem cell and the prolif-
erative demand to which it is subjected, reach a Hayflick limit during the life span of the patient. Although signifi-
cant shortening of telomeres is reported to occur within the first year posttransplantation, as yet no evidence has
indicated that this shortening is associated with marrow function. In this review, we summarize reports on telomere
shortening in stem cell transplantation recipients and report 2 cases in which graft failure is associated with signifi-
cant telomere shortening.
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determined that the telomere length of cells in the marrow
graft was 0.4 to 2 kb shorter than the pretransplantation
telomere length detected in the donor, although the source
of samples (ie, sorted or unsorted leukocytes, neutrophils, or
mononuclear cells from peripheral blood) and the observa-
tion period varied among studies [11-14]. Mathioudakis et
al. looked at 17 marrow transplantation survivors with a fol-
low-up of 19 to 28 years and found telomeres shortened on
average 0.94 kb [15]. More recent data obtained from 25
stem cell transplant recipients showed that, on average, a
0.5-kb decrease in telomere length occurred within the
first year [16] with very little, if any, decrease thereafter
[17]. This observation supports the notion that an
increased replicative demand on stem cells during the
period of hematopoietic reconstitution results in measur-
able telomere shortening. This finding is also supported by
data indicating that the extent of telomere shortening is
inversely correlated with the number of nucleated cells
transplanted [11,14].
Although most studies indicate some degree of acceler-
ated telomere shortening in transplant recipients, the degree
of shortening, at least for the majority of patients, does not
appear to reach a level that compromises marrow function.
This circumstance could change with longer follow-up or in
cases in which very few donor stem cells were transplanted
or in which donor cells, because of age or unknown reasons,
have unusually short telomeres. In these instances, it is rea-
sonable to speculate that telomere shortening could reach a
critical level resulting in senescence of hematopoietic cells
that, in turn, could compromise marrow function. A linkage
between telomere dysfunction and marrow failure is
strongly supported by recent data indicating that haploin-
sufﬁciency for the telomerase RNA gene typically results in
aplastic anemia [18]. In this review, we summarize 2 cases in
which telomere shortening may have played a role in poor
graft function.
CASE 1: OLD MARROW INTO A YOUNG RECIPIENT
A 7-year-old male patient received a bone marrow
transplant from his paternal grandmother for acute lym-
phoblastic leukemia (ALL) in second complete remission
(CR). The age of the donor was 61 years. Pretransplanta-
tion conditioning consisted of 1440 cGy total body irradia-
tion (TBI) and cyclophosphamide (120 mg/kg). A total of
4.04 ×108/kg nucleated cells was infused. Donor and recipi-
ents were serologically identical at HLA-A, -B, and -C,
with a single-allele, unidirectional mismatch at DRB1 in
the direction of graft-versus-host disease (GVHD). The
patient’s peripheral blood counts showed stable engraft-
ment. Cytogenetic and fluorescence in situ hybridization
(FISH) analyses of the bone marrow revealed all donor-
derived cells during the entire course of treatment. Despite
successful engraftment of the donor cells, the patient expe-
rienced low absolute neutrophil counts (800-900/mm3) at
25 months after transplantation, with a further drop to
302/mm3 at 32 months. The hematocrit and platelet levels
also decreased to 25% and 125,000/mm3, respectively. At
the time of this report, the patient needed granulocyte
colony-stimulating factor and erythropoietin to maintain
his neutrophil and red cell counts. Poor marrow function
could not be attributed to the most common causes of
myelosuppression, including drugs, viral infections, relapse,
rejection, or GVHD.
Considering the donor age at the time of transplanta-
tion, we measured telomere length in subsets of leukocytes
obtained from peripheral blood of the recipient and donor
(Table 1) using FISH and ﬂow cytometry [19,20] with modi-
fications that allow analysis of subsets within the same
sample ([21] and G.M.B. and P.M.L., unpublished data).
Telomere length values in subsets of cells obtained from the
donor were comparable to those of age-matched control val-
ues for the same cell populations derived from a reference
group of 400 healthy individuals. However, posttransplanta-
tion donor cells harvested from the patient were 0.8 to 2.0 kb
shorter. This ﬁnding indicates that this young patient has a
hematopoietic system with telomere lengths that are signiﬁ-
cantly shorter than those of his age-matched controls.
CASE 2: A LONG-TERM SURVIVOR WHO DEVELOPED
MARROW FAILURE
This patient underwent an HLA-matched transplanta-
tion of bone marrow from his sister for the treatment of
severe aplastic anemia. At the time of transplantation the
patient was 13 years old and the donor was 14 years old.
The patient received 200 mg/kg of cyclophosphamide as a
preparatory regimen and methotrexate for GVHD prophy-
laxis for 3 months. A total of 2.9 × 108/kg nucleated cells
was infused. The transplant engrafted well and the patient
had normal blood counts until 25 years after transplanta-
tion, when abnormal counts were noted: white blood cells
1100/mm3, absolute neutrophil counts 310/mm3, hematocrit
33.3%, and platelet counts 32,000/mm3. The patient’s bone
marrow was shown to be hypocellular. Although hepatitis C
also had been diagnosed and the patient showed signs of
hypersplenism, the results of bone marrow examination
excluded the possibility that hypersplenism caused the pan-
cytopenia. FISH analysis results of marrow and peripheral
Table 1. Telomere Length Measurements after Transplantation
Normal Telomere
Median Length at Age
Telomere (50th Percentile),
Age Cell Type Length, kb kb* 
Donor 64 Monocytes 9.9† 10.1
Lymphocytes 8.3† 7.8
Naïve T-cells 8.3† 8.3
Memory T-cells 7.2† 7.1
B-cells 10.3† 9.8
Recipient 10 Monocytes 8.3‡ 12.5
Lymphocytes 6.5‡ 11.7
Naïve T-cells 6.4‡ 12.1
Memory T-cells 6.4‡ 10.7
B-cells 8.3‡ 12.0
*Values are based on the data from 400 healthy individuals aged 0
to 102 years (G.M.B and P.M.L., unpublished data).
†Normal telomere length: values between the 10th and 90th per-
centile of age-matched controls.
‡ Very low telomere length: values below the ﬁrst percentile of age-
matched controls.
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blood showed more than 96% donor-derived hemato-
poiesis. When the patient developed pancytopenia, telom-
ere length in blood mononuclear cells of the recipient was
an estimated 2.2 kb shorter compared to that of the donor
(recipient, 5.2 kb; donor 7.4 kb) (Table 2).
TELOMERE SHORTENING: A POSSIBLE MECHANISM FOR
LATE GRAFT FAILURE?
Several cross-sectional studies have shown that the
telomere length in nucleated blood cells from healthy indi-
viduals shortens with age at a rate of 30 to 50 bp per year
[12-14,22,23]. It is tempting to use this type of data to
translate the degree of telomere loss observed in transplant
recipients into equivalent years of normal aging. In the
2 cases that were presented here, this type of calculation
yielded 27 to 67 years of “telomere aging” in case 1 and 44 to
73 years in case 2. However, there are several pitfalls in this
type of calculation. First, the figure for the telomere loss
with age is calculated using cross-sectional rather than lon-
gitudinal data. Given the marked variation in telomere
length at any given age, the rates of shortening could differ
between healthy individuals. Longitudinal data are essential
to address this issue but are currently not available. Fur-
thermore, it is known that the loss of telomeres in leuko-
cytes with age is not linear and, for example, occurs at a
much higher rate in children than in adults [20,24].
Although such differences have been primarily related to
stem cell turnover [20], it is becoming increasingly clear
that oxidative stress is an important contributor to telomere
loss (reviewed in [25]). Such nonreplicative telomere short-
ening complicates the use of telomere length in cells as a
measure of their mitotic or chronological age. Finally, the
telomere length at which cells are unable to continue cell
division may vary between individuals [26], depending on,
for example, the expression level of telomere binding pro-
teins [26] and/or levels of functional telomerase. The latter
is illustrated in tumor cells and immortalized cell lines,
which can have short telomeres that are stabilized by
telomerase [8].
On the other hand, several studies support the idea that
telomere shortening in hematopoietic stem cells may com-
promise their function and the ability of the hematopoietic
system to meet proliferative demands. Patients with the rare
disorder dyskeratosis congenita typically die before the age
of 50 from complications of aplastic anemia, immune deﬁ-
ciency, or cancer (reviewed in [27]). Patients with this disor-
der typically show decreased telomerase activity, eg, resulting
from a mutation in the telomerase RNA component (TERC)
gene [18]. Strikingly, such a defect gives rise to an autosomal
dominant disorder, indicating that even partial telomerase
deﬁciency is poorly tolerated in humans. In contrast, com-
plete lack of telomerase is tolerated for up to 6 generations in
mice [28]. Most likely, telomere shortening evolved as a
tumor suppressor mechanism in long-lived species (reviewed
in [29]). Telomere length data in patients with dyskeratosis
congenita and aplastic anemia (see, eg, [30-33]) provide
strong support for a linkage between replicative potential
and telomere length in hematopoietic stem cells.
Problems related to telomeres in recipients of stem cell
transplants are to some extent predictable and in most
cases preventable. Transplantation of a very limited num-
ber of stem cells will put high demands on their prolifera-
tive potential. This situation may eventually result in
exhaustion of stem cells and aplastic anemia, especially if
telomeres in donor stem cells were short to start with. In
this respect cord blood cells may have a significant advan-
tage that may outweigh concerns about the limited number
of cells that are typically available for transplantation.
Long-term survivors of stem cell grafts containing limited
numbers of stem cells (or large numbers of compromised
stem cells) could be particularly at risk if extra demands are
put on the hematopoietic system, eg, as a result of chronic
infection.
Currently no precise associations have been discovered
between telomere lengths on a specific chromosome and a
specific functional abnormality. Therefore exactly what
constitutes functionally relevant telomere shortening in
the transplantation setting remains to be determined.
Regarding the example provided by “Old Marrow into
Young Recipient,” one might argue that aplasia due to
telomere shortening should not be responsive to growth
factors, but we do not know enough to make that assump-
tion. Growth factors might provide a survival signal to an
otherwise compromised cell. It is reasonable to speculate
in this case, however, that treatment with growth factors
will only accelerate telomere shortening, leading eventu-
ally to greater genetic instability, loss of responsiveness to
growth factors, and/or apoptosis. More data are urgently
needed on telomere length associated with various subpop-
ulations of hematopoietic cells in healthy individuals and
patients with hematological disorders and with age and
disease progression. Given the increasing number of long-
term survivors of stem cell transplantation and the increas-
ing age of donors, it is important to consider that loss of
telomeres in donor stem cells could eventually compromise
marrow function.
ACKNOWLEDGMENTS
This work was supported by grants AI29524, HL62923,
and CA18029 from the National Institutes of Health and by
grant MOP38075 from the Canadian Institute of Health
Research. G.M.B. was supported by a grant from the Swiss
Science Foundation.
Table 2. Telomere Length Measurements after Transplantation
Normal Telomere
Median Length at Age
Telomere (50th Percentile),
Age Cell Type Length, kb kb* 
Donor 42 Mononuclear cells 7.4† 8.7
Recipient 40 Mononuclear cells 5.2‡ 8.8
*Values are based on the data from 400 healthy individuals aged 0
to 102 years (G.M.B. and P.M.L., unpublished data).
†Normal telomere length: values between the 10th and 90th per-
centile of age-matched controls.
‡Very low telomere length: values below the ﬁrst percentile of age-
matched controls.
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